denecimig   Click here for help

GtoPdb Ligand ID: 14697

Synonyms: Frehemgo® | MIM-8 | mim8 | NN-7769 | NN7769 | NNC-0365-3769 | NNC0365-3769
Compound class: Antibody
Comment: Denecimig (Mim8) is a bispecific antibody that functions as a factor VIII mimetic that bridges between Factor IXa and Factor X to promote clotting [1-4]. The FX-binding arm is engineered with low binding affinity to minimise target-mediated clearance, whilst the anti-FIXa arm binds more strongly and enhances the proteolytic activity of FIXa [1].
Click here for help
References
1. Østergaard H, Lund J, Greisen PJ, Kjellev S, Henriksen A, Lorenzen N, Johansson E, Røder G, Rasch MG, Johnsen LB et al.. (2021)
A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice.
Blood, 138 (14): 1258-1268. [PMID:34077951]
2. Eduarda Alves de Jesus V, Lamounier de Almeida D, Muniz Júnior RL, Alvares-Teodoro J, Pierce GF, Camelo RM. (2026)
Factor-VIII mimetic bispecific antibodies for the treatment of hemophilia A: an update.
Expert Rev Clin Pharmacol, 19 (3): 219-238. [PMID:41728921]
3. Lauritzen B, Bjelke M, Björkdahl O, Bloem E, Keane K, Kjalke M, Rossen M, Lippert SL, Weldingh KN, Skydsgaard M et al.. (2022)
A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys.
J Thromb Haemost, 20 (6): 1312-1324. [PMID:35191180]
4. Matsushita T, Nogami K, Shanmukhaiah C. (2026)
FVIIIa Mimetics: New Approaches and Next-Generation Initiatives.
Haemophilia, [Epub ahead of print]. [PMID:41988951]